Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer
October 04 2022 - 8:25AM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced the appointment of
Andrew L. Concoff M.D. FACR, CAQSM as Chief Innovation Officer. In
this role, Dr. Concoff will lead the company’s rheumatoid arthritis
medical initiatives, including the AVISE® RADR platform (Rheumatoid
Arthritis Drug Response). Dr. Concoff will be a key principal in
strategy, business development, portfolio management, pipeline
prioritization, and formation of new business ventures, as well as
the advancement of innovative access partnerships with payors and
governments globally.
“Exagen is deeply committed to rheumatology where we believe
there are significant unmet needs in the diagnosis, prognosis, and
monitoring of autoimmune diseases, that our tests can uniquely
address,” said Ron Rocca, President and Chief Executive Officer,
Exagen. “We are delighted to welcome Dr. Concoff to our Executive
Leadership Team as we enter the next phase of innovation for
Exagen. We believe his clinical experience in rheumatology and
leadership will be instrumental in our pursuit to transform the
care continuum for patients suffering from autoimmune
diseases.”
Dr. Concoff has more than fifteen years of clinical practice in
rheumatology, having completed his fellowship at the University of
California, Los Angeles. He earned a B.S. in Psychobiology from
UCLA, an M.D. from the University of Texas Medical School at
Houston where he also completed coursework toward a Master’s in
Clinical Research. Dr. Concoff joins Exagen from United
Rheumatology, where his work as Executive Vice President, Chief
Medical Officer enables him to create, model, and implement
value-based programs with payors, quality improvement initiatives
with pharmaceutical manufacturers, and other clinical care
innovations with stakeholders across the musculoskeletal ecosystem.
He is also a Fellow of the American College of Rheumatology and has
served on numerous national guideline committees, most recently as
Chair of the Knee Osteoarthritis and Ultrasound Guideline
Committees for United Rheumatology.
“By committing to develop individualized testing that predicts
medication response in rheumatoid arthritis, Exagen has vaulted to
the vanguard of the precision revolution in rheumatology. My role
will be to foster an environment that maximizes the impact of
transformative laboratory capabilities, such as this, across the
rheumatology ecosystem. Our goal is to turn guesses into answers,”
said Dr. Concoff, “providing physicians, and their patients, with
the personalized results they need to aim higher, toward previously
unattainable levels of autoimmune disease control and health. The
spirit of pioneering scientific innovation is alive and well at
Exagen and we plan to harness it to generate testing that brings
the future that patients and clinicians have longed for to the
clinics where they meet.”
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider of autoimmune
diagnostic, prognostic, and monitoring testing
solutions. Exagen is a patient focused, discovery driven
organization built on the success of AVISE® testing and is
investing in its product pipeline to support patients throughout
their autoimmune diagnosis and treatment journeys. The goal
at Exagen is to assist patients, physicians, and payors
by enabling precision medicine. Exagen is located
in San Diego County with clinical and research and
development laboratories in Vista, CA.
For more information, please visit Exagen.com and
follow @ExagenInc on Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on Exagen’s
current beliefs and expectations. Such forward-looking statements
include, but are not limited to, statements regarding the expected
benefit of Dr. Concoff’s employment with Exagen, including the
development of the AVISE® RADR platform. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be
achieved. Actual results may differ from those set forth in this
press release due to the risks and uncertainties inherent in
Exagen’s business, including, without limitation: the COVID-19
pandemic may continue to adversely affect its business, financial
condition and results of operations, including as a result of
slowdown in its operations as well as those of its suppliers and
courier services, impeding patient movement and interruptions to
healthcare services causing a decrease in test volumes, disruptions
to the supply chain of material needed for its tests causing an
increase in cost per test, its sales and commercialization
activities and its ability to receive specimens and perform or
deliver the results from its tests, delays in reimbursement and
coverage decisions from Medicare and third-party payors and in
interactions with regulatory authorities, and delays in ongoing and
planned clinical trials involving its tests; Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payors and others in the
medical community; Exagen’s ability to successfully execute on its
business strategies; third-party payors not providing coverage and
adequate reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect funds due;
expectations regarding its pipeline products, including the
development of the AVISE® RADR platform; Exagen’s ability to obtain
and maintain intellectual property protection for its testing
products; regulatory developments affecting Exagen’s business; and
other risks described in Exagen’s prior press releases and Exagen’s
filings with the Securities and Exchange
Commission (“SEC”), including under the heading “Risk Factors”
in Exagen’s Annual Report on Form 10-K for the year
ended December 31, 2021 and any subsequent filings with
the SEC. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and Exagen undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date hereof. All forward-looking statements are
qualified in their entirety by this cautionary statement, which is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995.
Investor Relations
Exagen Inc.
Ryan Douglas
rdouglas@exagen.com
760.560.1525
Company
Exagen Inc.
Kamal Adawi, Chief Financial Officer
kadawi@exagen.com
760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Jul 2023 to Jul 2024